OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System
OrthoPediatrics (NASDAQ: KIDS) has announced the expansion of its Trauma and Deformity portfolio with the 3P™ Pediatric Plating Platform™ Hip System, marking the company's 5th FDA approval in 2025. This innovative plate and screw platform aims to modernize trauma and deformity correction treatment in lower extremities.
The beta launch of 3P Hip will be followed by 3P Small/Mini in early 2026, with additional systems planned for future release. This initiative represents one of the company's largest product developments in its Trauma and Deformity division, aimed at creating the most comprehensive modern plating portfolio in pediatric orthopedic history.
OrthoPediatrics (NASDAQ: KIDS) ha annunciato l'espansione del suo portafoglio Trauma e Deformità con il 3P™ Pediatric Plating Platform™ Hip System, segnando la quinta approvazione FDA dell'azienda nel 2025. Questa innovativa piattaforma di placche e viti punta a modernizzare il trattamento di traumi e correzioni di deformità agli arti inferiori.
Il lancio beta del 3P Hip sarà seguito dal 3P Small/Mini all'inizio del 2026, con ulteriori sistemi previsti per il futuro. Questa iniziativa rappresenta uno dei più grandi sviluppi di prodotto nella divisione Trauma e Deformità dell'azienda, con l'obiettivo di creare il portafoglio di placche moderne più completo nella storia dell'ortopedia pediatrica.
OrthoPediatrics (NASDAQ: KIDS) ha anunciado la expansión de su portafolio de Trauma y Deformidades con el 3P™ Pediatric Plating Platform™ Hip System, marcando la quinta aprobación de la FDA para la compañía en 2025. Esta innovadora plataforma de placas y tornillos tiene como objetivo modernizar el tratamiento de trauma y corrección de deformidades en las extremidades inferiores.
El lanzamiento beta del 3P Hip será seguido por el 3P Small/Mini a principios de 2026, con sistemas adicionales planeados para futuros lanzamientos. Esta iniciativa representa uno de los desarrollos de producto más grandes de la compañía en su división de Trauma y Deformidades, con la finalidad de crear el portafolio de placas más moderno y completo en la historia de la ortopedia pediátrica.
OrthoPediatrics (NASDAQ: KIDS)는 3P™ Pediatric Plating Platform™ Hip System을 통해 외상 및 기형 치료 제품군을 확장한다고 발표했으며, 이는 2025년에 회사가 받은 다섯 번째 FDA 승인입니다. 이 혁신적인 판 및 나사 플랫폼은 하체 외상 및 기형 교정 치료를 현대화하는 것을 목표로 합니다.
3P Hip의 베타 출시 후 2026년 초에 3P Small/Mini가 이어질 예정이며, 추가 시스템도 향후 출시 계획에 포함되어 있습니다. 이번 이니셔티브는 회사 외상 및 기형 부서에서 가장 큰 제품 개발 중 하나로, 소아 정형외과 역사상 가장 포괄적인 현대식 판 제품군을 구축하는 것을 목표로 합니다.
OrthoPediatrics (NASDAQ : KIDS) a annoncé l'expansion de son portefeuille Trauma et Déformation avec le 3P™ Pediatric Plating Platform™ Hip System, marquant la cinquième approbation FDA de l'entreprise en 2025. Cette plateforme innovante de plaques et vis vise à moderniser le traitement des traumatismes et des corrections de déformations des membres inférieurs.
Le lancement bêta du 3P Hip sera suivi par le 3P Small/Mini début 2026, avec d'autres systèmes prévus pour une sortie future. Cette initiative représente l'un des plus grands développements de produits de la division Trauma et Déformation de l'entreprise, visant à créer le portefeuille de plaques modernes le plus complet de l'histoire de l'orthopédie pédiatrique.
OrthoPediatrics (NASDAQ: KIDS) hat die Erweiterung seines Trauma- und Deformitätsportfolios mit dem 3P™ Pediatric Plating Platform™ Hip System angekündigt, was die fünfte FDA-Zulassung des Unternehmens im Jahr 2025 markiert. Diese innovative Platte- und Schraubenplattform zielt darauf ab, die Behandlung von Traumata und Deformitätskorrekturen an den unteren Extremitäten zu modernisieren.
Auf den Beta-Start des 3P Hip folgt Anfang 2026 der 3P Small/Mini, mit weiteren Systemen, die für die Zukunft geplant sind. Diese Initiative stellt eine der größten Produktentwicklungen der Trauma- und Deformitätsabteilung des Unternehmens dar und hat das Ziel, das umfassendste moderne Plattenportfolio in der Geschichte der pädiatrischen Orthopädie zu schaffen.
- Received 5th FDA approval in 2025, demonstrating strong regulatory momentum
- Expanding product portfolio with innovative trauma and deformity treatment solutions
- Strategic rollout planned with multiple system launches through 2026
- Potential for increased market share in pediatric orthopedic plating segment
- None.
Insights
OrthoPediatrics' new 3P Hip System strengthens their pediatric orthopedic portfolio, representing strategic expansion with long-term growth potential.
OrthoPediatrics has secured its fifth FDA approval of 2025 with the 3P™ Pediatric Plating Platform™ Hip System, marking a significant expansion of their trauma and deformity correction portfolio. This approval initiates what appears to be a comprehensive multi-year product rollout strategy, with the 3P Small/Mini system planned for early 2026 and additional systems in subsequent years.
The strategic importance of this platform cannot be overstated. Management describes it as "one of the largest product endeavors" in the company's trauma and deformity division history, suggesting substantial R&D investment and long-term growth expectations. The planned sequential releases indicate a methodical approach to eventually transforming their entire plate and screw product portfolio.
What makes this platform potentially valuable is its focus on addressing specific operational challenges in pediatric orthopedic surgery. The system promises improved surgical workflow and inventory efficiency - critical factors for hospital adoption in today's cost-conscious healthcare environment. The emphasis on "unique implants and instruments" suggests proprietary technology that could differentiate OrthoPediatrics from competitors.
For specialized medical device companies, portfolio breadth directly correlates with market penetration. Each new system creates additional touchpoints with surgeons and hospitals, potentially driving deeper customer relationships. Management's reference to "share-taking opportunities" signals confidence in the platform's competitive positioning within their niche market.
By maintaining exclusive focus on pediatric orthopedics rather than diversifying into broader markets, OrthoPediatrics continues to deepen its specialized expertise in an underserved segment where larger medical device companies typically invest less resources.
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and Deformity portfolio with 3P™ Pediatric Plating Platform™ Hip System, the first of several systems in the 3P family. This represents the company’s 5th FDA approval in 2025.
3P Pediatric Plating Platform Hip System is a new plate and screw platform to modernize and revolutionize trauma and deformity correction treatment in the lower extremities. This family of plating systems will provide surgeons unparalleled coverage for a variety of Trauma and Deformity correcting indications by delivering unique implants and instruments to improve surgical workflow and inventory efficiency. The beta launch for 3P Hip is expected to be followed by the next system, 3P Small/Mini, early in 2026, followed by expected launches of additional systems in the upcoming years. Once complete the result we be the complete transformation of the Company’s plate and screw product portfolio, giving OrthoPediatrics the most robust and modern plating portfolio in pediatric orthopedic history.
OrthoPediatrics Trauma and Deformity division President, Joe Hauser commented “The 3P Pediatric Plating Platform is a world-class system with significant opportunity to fill unmet needs. This family of systems is one of the largest product endeavors that we've taken on within the Trauma and Deformity side in our company history, and we are excited for 3P Hip to be the first step to further share-taking opportunities within the plating franchise.”
CEO, David Bailey echoed those comments, saying “We continue to focus on providing surgeons with a comprehensive portfolio of innovative orthopedic treatments to address all unmet needs for pediatric patients, and the latest FDA approval for the 3P Hip System marks our 5th FDA approval thus far in 2025. I’m incredibly proud of the work our R&D team has done to achieve this goal and look forward to the addition of many more products in the future as we continue to expand our portfolio.”
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406
FAQ
What is OrthoPediatrics' new 3P Pediatric Plating Platform Hip System?
When will KIDS stock launch the 3P Small/Mini system?
How many FDA approvals has OrthoPediatrics (KIDS) received in 2025?
What is the significance of the 3P platform for OrthoPediatrics (KIDS)?
